May 2025 - BioMedWire (BMW)

FridayMay 16, 2025 10:00 am

New Multimodal AI System Boosts the Accuracy of Lung Cancer Screening

Early diagnosis of lung cancer is pivotal to effective treatment because this disease is very challenging to treat. Advances in AI are transforming the screening for this disease, improving both efficiency and accuracy. Existing screening methods such as low-dose CT have several challenges. These include high rates of false-positives and a high variability when reporting other incidental but critical information, such as findings on cardiovascular diseases. Furthermore, the shortage of radiologists around the world means that less than 10% of people who need low-dose CT scans can actually undergo them. New research published in the journal Nature Communications shows that…

ThursdayMay 15, 2025 10:00 am

Will Trump’s Executive Order on Drug Prices Yield the Desired Results

While President Trump signed an order aimed at reducing the high cost of prescription drugs in the U.S., it isn’t clear how exactly the price reduction will be achieved and how such reductions could impact the country in the long term. The President said patients in America pay a lot more for prescription drugs than the cost incurred for the same drugs in other countries. He added that he was going to order drug firms to slash their prices within the U.S. There has been a growing concern about the high cost of prescription drugs in America and data exists…

TuesdayMay 13, 2025 10:00 am

Study Links Higher Consumption of Ultra-Processed Foods to Heightened Psoriasis Risk

A recently conducted study has found a strong link between the intake of ultra-processed foods (UPFs) and a higher risk of developing psoriasis. The findings of this research appeared in the Nutrients journal. People suffering from psoriasis have lesions/patches that are itchy, scaly and inflamed. They commonly affect the nails, soles and palms, although the condition can manifest on any part of the body. The condition can also elevate the risk of a number of mental health problems, such as anxiety and depression, in addition to increasing the risk for Crohn’s disease and cardiovascular disease. While there currently isn’t a…

TuesdayMay 13, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch

The opioid epidemic has prompted a re-evaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention Nutriband’s AVERSA(TM) Fentanyl represents a significant advancement in this domain The company’s strategic development of AVERSA Fentanyl follows a structured pharmaceutical lifecycle As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach (https://ibn.fm/jhHMY). The…

FridayMay 09, 2025 10:00 am

Study Reveals Early Development of Pediatric Brain Tumors in Specialized Nerve Cells

Medulloblastoma is a commonly occurring pediatric brain cancer in kids and adolescents. The cancer develops within the cerebellum, the part of the brain responsible for coordinating movement and other functions. These tumors enlarge quickly, can grow into nearby tissues, and in some cases, can metastasize. The variations in these tumors make it challenging to find appropriate treatments. Now a recent study in Germany has come up with findings which shed light on the exact location where these aggressive tumors normally first develop. The findings appeared in the Nature journal. The study’s first author Konstantin Okonechnikov explains that they genetically characterized…

FridayMay 09, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

Nutriband’s AVERSA(TM) technology is advancing toward commercialization as the first abuse-deterrent transdermal fentanyl patch Recent FDA regulatory changes underscore the urgent need for safer opioid delivery methods and responsible prescribing Strategic milestones with partner Kindeva and a strengthened global IP portfolio position Nutriband for long-term growth A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid…

ThursdayMay 08, 2025 10:00 am

Eye Exam Could Help in Detecting Parkinson’s Disease Early, Study Suggests

New research suggests that a simple examination of the retina could provide an early diagnosis of Parkinson’s disease. Universite Laval researchers conducted this study and their findings appeared in the Neurobiology of Disease journal. According to the researchers, the retinas of individuals having Parkinson’s don’t respond in the same way to light stimulus as those of individuals without the disease. Prof. Martin Levesque, the study leader, explains that currently, people are only diagnosed with Parkinson’s after consulting their doctor regarding tremors and other motor problems. By this time, Levesque adds, the disease has progressed to such an extent that central…

WednesdayMay 07, 2025 10:30 am

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’

INBS offers a patented, non-invasive testing solution positioned to disrupt a global drug screening market projected to reach $14.9 billion by 2030. The company is revenue-generating, with 148% year-over-year growth in FY 2024 and 450+ active customer accounts. Its Intelligent Fingerprinting system provides rapid, on-site results with a lower cost and higher convenience compared to traditional methods. The Intelligent Fingerprinting Drug Screening System is already in commercial use internationally, and a U.S. product launch is planned for 2025, with FDA 510(k) clearance in process and new patent protections underway. INBS is led by a seasoned executive team with global healthcare…

TuesdayMay 06, 2025 10:00 am

Study: Women with Lung Cancer Have Worse Outcomes Due to Genes Linked to Pregnancy

According to a study conducted recently at Memorial Sloan Kettering (MSK) Cancer Center, lung cancer co-opts some genes usually involved in helping fetuses to grow. The lung cancer leverages these genes to evade the immune system of the patient. The researchers found that because of this, women in whom these genes were activated tended to have poorer outcomes. This analysis suggests that targeting those genes could have a beneficial effect of improving the clinical outcomes of females diagnosed with lung cancer. The researchers presented their findings at this year’s annual meeting of the American Association of Cancer Research. Jung Hun,…

FridayMay 02, 2025 10:00 am

Data Shows When Hospitals Exit MA Plans, Enrollees Also Leave

For a variety of reasons, hospitals can disagree with Medicare Advantage insurance providers and they part ways. When a hospital cancels or fails to renew its contract with a health insurer, the patients who had coverage with that insurer often have to choose between staying with that insurer and getting care from the shrinking network of providers or ditch the MA plan. Reports indicate that thousands of patients ditch MA plans once the health insurer and hospital fail to continue their relationship. To understand why MA plan holders end up switching insurers or reverting to the government-run Medicare, consider an…